Fourth, selective antagonism of the Gal-9 N-CRD or C-CRD either independently or together enables fine tuning of cell type-directed effects based on unique lineage glycosylation and Gal-9 binding profiles, e.g., T-cells vs. macrophages vs. tumor cells [219,220,221,222]. The gene discussed is LGALS9; the disease is neoplasm.